At the moment, SGLT-2 inhibitors such as empagliflozin and dapagliflozin are also approved for the treatment of chronic heart failure, regardless of left ventricular ejection fraction, as well as for reducing cardiovascular events and the risk of kidney disease progression in patients with chronic kidney disease [1,5,6,7,8,9]. The gene discussed is SLC5A2; the disease is chronic kidney disease.